Skip to main content
main-content

Canagliflozin

News

01-02-2019 | Canagliflozin | medwireNews | News

No fracture risk found with canagliflozin in real-world data

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

Source:

Ann Intern Med 2019; doi:10.7326/M18-0567
Ann Intern Med 2019; doi:10.7326/M18-3550

11-14-2018 | SGLT2 inhibitors | News

Registry study supports SGLT2 inhibitor amputation risk

A registry study in The BMJ finds a small but significant increased risk for amputations in patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors.

Source:

BMJ 2018; 363: k4365

11-12-2018 | SGLT2 inhibitors | News

Meta-analysis supports cardioprotective benefits of SGLT2 inhibitors

Sodium-glucose cotransporter 2 inhibitors reduce the risk for heart failure hospitalization and renal disease progression in patients with type 2 diabetes regardless of existing cardiovascular disease, meta-analysis data show.

Source:

Lancet 2018; doi:10.1016/S0140-6736(18)32590-X
Lancet 2018; doi:10.1016/S0140-6736(18)32824-1

08-15-2018 | SGLT2 inhibitors | Highlight | News

Research adds to SGLT2 inhibitor amputation risk debate

Researchers have found evidence to support an increased risk for amputation among patients with type 2 diabetes taking sodium-glucose cotransporter 2 inhibitors relative to some oral treatments.

Source:

JAMA Int Med 2018; doi:10.1001/jamainternmed.2018.3034
JAMA Int Med 2018; doi:10.1001/jamainternmed.2018.3025

07-16-2018 | SGLT2 inhibitors | Highlight | News

No significant increase in amputation risk with SGLT2 inhibitors in real-world study

Patients with type 2 diabetes who are treated with sodium-glucose cotransporter 2 inhibitors have numerically higher rates of amputation than those given dipeptidyl peptidase-4 inhibitors, but the difference does not reach statistical significance, researchers report.

Source:

Diabetes Obes Metab 2018; doi:10.1111/dom.13459

07-10-2018 | Canagliflozin | News

CANVAS analysis supports canagliflozin CV benefit at low renal function

A secondary analysis of the CANVAS trial supports the beneficial cardiovascular and renal effects of sodium-glucose cotransporter 2 inhibition down to a low level of kidney function.

Source:

Circulation 2018; doi:10.1161/CIRCULATIONAHA.118.035901

07-03-2018 | Canagliflozin | News

CANVAS data support renoprotective effect of canagliflozin in type 2 diabetes

Canagliflozin reduces the risk for loss of kidney function, estimated glomerular filtration rate decline, and albuminuria versus placebo in people with type 2 diabetes at high risk for cardiovascular events, CANVAS Program data show.

Source:

Lancet Diabetes Endocrinol 2018; Advance online publication

06-29-2018 | Canagliflozin | Highlight | News

OBSERVE-4D: Canagliflozin amputation risk not replicated in real-world data

A study of patients from US administrative claims databases finds no evidence that use of canagliflozin increases the risk for below the knee amputation when compared with other sodium-glucose cotransporter 2 inhibitors or with other antidiabetic medications.

Source:

Diabetes Obes Metab 2018; Advance online publication

03-12-2018 | Canagliflozin | Highlight | News

CANVAS analysis supports SGLT2 inhibitor benefits for HF

The latest analysis of the CANVAS trial indicates that the cardiovascular benefits of canagliflozin in patients with type 2 diabetes may be greatest in those with concomitant heart failure.

Source:

Circulation 2018; Advance online publication

02-08-2018 | Cardiovascular outcomes | News

Further support for cardiovascular benefits of canagliflozin

Results of a US database study suggest that the sodium-glucose co-transporter-2 inhibitor canagliflozin is associated with a lower risk for heart failure hospitalization compared with three other classes of antidiabetes agent.

Source:

BMJ 2018; 360: k119

11-14-2017 | Canagliflozin | News

Canagliflozin benefits may extend to primary prevention

Further analysis of the CANVAS trial suggests that the benefits of canagliflozin treatment are broadly consistent in type 2 diabetes patients with and without pre-existing cardiovascular disease,

Source:

Circulation 2017; Advance online publication

08-01-2017 | Canagliflozin | News

Cardiac biomarker data support canagliflozin cardioprotective effect

Treatment with canagliflozin has positive effects on biomarkers of cardiovascular disease risk in older patients with type 2 diabetes, research shows.

Source:

J Am Coll Cardiol 2017; 70: 704–712, 713–714

07-31-2017 | SGLT2 inhibitors | News

No evidence for increased overall cancer risk with SGLT2 inhibitors

Results of a systematic review and meta-analysis suggest that patients with type 2 diabetes who are treated with sodium–glucose cotransporter 2 inhibitors do not have a higher overall cancer risk than patients not receiving these therapies.

Source:

Diabetologia 2017; Advance online publication

06-14-2017 | Canagliflozin | ADA 2017 | News

Integrated CANVAS: canagliflozin offers cardioprotection at amputation cost

The integrated results of the CANVAS and CANVAS-R studies show that canagliflozin reduces the risk for cardiovascular and renal events in patients with type 2 diabetes at high cardiovascular risk.

Source:

N Engl J Med 2017; Advance online publication

06-12-2017 | Medications | ADA 2017 | News

Research round-up: medications for type 2 diabetes

One of the final sessions on Saturday featured the presentation of new, and mostly positive, data on medications for glycemic control in patients with type 2 diabetes.

03-20-2017 | SGLT2 inhibitors | News

CVD-REAL extends EMPA-REG findings to real-world patients

Findings from the CVD-REAL trial show a protective effect of sodium glucose cotransporter-2 inhibitors against heart failure in real-world patients with type 2 diabetes.

Source:

American College of Cardiology 66th Annual Scientific Session; Washington, DC, USA: 17–19 March 2017

12-02-2016 | Hypoglycemia | News

Adjunct canagliflozin improves glycemic variability in type 1 diabetes

Canagliflozin improves glycemic variability and treatment satisfaction in patients with type 1 diabetes using the sodium glucose cotransporter 2 inhibitor as an add-on to insulin, show findings from a randomized trial.

Source:

Diabetes Care 2016; Advance online publication

image credits